The patent badge is an abbreviated version of the USPTO patent document. The patent badge does contain a link to the full patent document.

The patent badge is an abbreviated version of the USPTO patent document. The patent badge covers the following: Patent number, Date patent was issued, Date patent was filed, Title of the patent, Applicant, Inventor, Assignee, Attorney firm, Primary examiner, Assistant examiner, CPCs, and Abstract. The patent badge does contain a link to the full patent document (in Adobe Acrobat format, aka pdf). To download or print any patent click here.

Date of Patent:
Apr. 10, 2018

Filed:

Aug. 22, 2016
Applicant:

Roche Innovation Center Copenhagen A/s, Horsholm, DK;

Inventors:

Majken Westergaard, Birkerod, DK;

Charlotte Albaek Thrue, Kobenhavn K, DK;

Frank Rasmussen, Roskilde, DK;

Henrik Frydenlund Hansen, Rodovre, DK;

Attorney:
Primary Examiner:
Int. Cl.
CPC ...
C12N 15/113 (2010.01); C07H 21/04 (2006.01); A61K 45/06 (2006.01); A61N 5/10 (2006.01); A61K 31/7088 (2006.01); C12N 15/11 (2006.01);
U.S. Cl.
CPC ...
C12N 15/113 (2013.01); A61K 31/7088 (2013.01); A61K 45/06 (2013.01); A61N 5/10 (2013.01); C07H 21/04 (2013.01); C12N 15/111 (2013.01); C12N 2310/11 (2013.01); C12N 2310/315 (2013.01); C12N 2310/3231 (2013.01); C12N 2310/341 (2013.01); C12N 2320/30 (2013.01);
Abstract

The present disclosure relates to an LNA oligonucleotide consisting of a sequence selected from the group consisting of 5'-()GGcaagcatccTG-3′ and 5′-()TTactgccttcTT-3′, wherein capital letters designate a beta-D-oxy-LNA nucleotide analog, small letters designate a 2-deoxynucleotide, underline designates either a beta-D-oxy-LNA nucleotide analog or a 2-deoxynucleotide, subscript 's' designates a phosphorothioate link between neighboring nucleotides/LNA nucleotide analogs, and subscript 'x' designates either a phosphorothioate link or a phosphorodiester link between neighboring nucleotides/LNA nucleotide analogs, and wherein the sequence is optionally extended by up to five 2-deoxynucleotide units. The LNA oligonucleotides are useful for modulating the expression of hypoxia-inducible factor-1a (HIF-1a), e.g. in the treatment of cancer diseases, inhibiting angiogenesis, inducing apoptosis, preventing cellular proliferation, or treating an angiogenic disease, e.g. diabetic retinopathy, macular degeneration (ARMD), psoriasis, rheumatoid arthritis and other inflammatory diseases.


Find Patent Forward Citations

Loading…